Expanding genomic medicine to enhance research and clincal care
Precision Initiatives to deliver rapid results to researchers and clinicians
Functional genomic studies fuel discovery of novel therapeutics
State-of-the-art infrastructure to support ground-breaking research initiatives
jQuery Slider


David Goldstein, PhD, Director of the Institute for Genomic Medicine
David Goldstein, PhD, Director of the Institute for Genomic Medicine

The Institute for Genomic Medicine was established in January of 2015 under the direction of Dr. David B. Goldstein as a part of Columbia University's Precision Medicine Initiative. The overarching goal of the institute is to create a cohesive, Columbia-wide research and teaching environment for human genetics and genomics. Recent technological advances in genome sequencing and adoption of electronic medical records have paved the way for the creation of patient-centered personalized medicine that will be one of the cornerstones of the medical field.

Columbia, the IGM, and IGM partners will help drive innovation in genomic medicine through vibrant research, clinical applications and outreach efforts. In support of these efforts, the institute is in the process of establishing a genetics environment that offers the benefits of scale and expertise to facilitate the integration of genomic analysis across the Columbia community.


Precision Medicine Helps Diagnose Child

A toddler was diagnosed by exome sequencing and successfully treated for a rare illness, demonstrating precision medicine's promise.

Read More

Recent Publications

Quinidine in the treatment of KCNT1 positive epilepsies. Mikati et al. 2015. Annals of Neurology

Additional evidence that PGAP1 loss of function causes autosomal recessive global developmental delay and encephalopathy. Williams et al. 2015. Clinical Genetics

Epileptic encephalopathy-causing mutations in DNM1 impair synaptic vesicle endocytosis. Dhinsda et al. 2015. Neurology Genetics

Clinical application of whole-genome sequencing in patients with primary immunodeficiency. Mousallem et al. 2015. Journal of Allergy and Clinical Immunology

Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Cirulli et al. 2015. Science

Whole-exome sequencing in undiagnosed genetic diseases: interpreting 119 trios. Zhu et al. 2015. Genetics in Medicine

De novo mutations in synaptic transmission genes including DNM1 cause epileptic encephalopathies. 2014. American Journal of Human Genetics


The Might Family

Read more about the Might Family in The New Yorker.